Related Experiment Video
Updated: Oct 22, 2025

Establishment of Epstein-Barr Virus Growth-transformed Lymphoblastoid Cell Lines
Published on: November 8, 2011
EBV+ lymphoproliferative diseases: opportunities for leveraging EBV as a therapeutic target
Keri Toner1,2,3,4, Catherine M Bollard1,3,4
1Center for Cancer and Immunology Research.
Abstract:
Epstein-Barr virus (EBV) is a ubiquitous human tumor virus, which contributes to the development of lymphoproliferative disease, most notably in patients with impaired immunity. EBV-associated lymphoproliferation is characterized by expression of latent EBV proteins and ranges in severity from a relatively benign proliferative response to aggressive malignant lymphomas. The presence of EBV can also serve as a unique target for directed therapies for the treatment of EBV lymphoproliferative diseases, including T cell-based immune therapies. In this review, we describe the EBV-associated lymphoproliferative diseases and particularly focus on the therapies that target EBV.
Related Concept Videos
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against...
Microorganisms in Medicine and Therapeutics

